Exciting news from Skinvisible Pharmaceuticals: Our licensee has had excellent results during their Phase 3 studies with our INVISICARE formulation for Netherton Syndrome. Read more: https://lnkd.in/gbVGqYNd
关于我们
Skinvisible, Inc., through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is an R&D pharmaceutical company that develops enhanced, patented topical and transdermal products to treat various conditions from obesity to acne to warts, along with rare skin disease and sunscreens, anti-aging products, hand sanitizing lotions, pre-surgical preparations, and medical treatments outside of dermatology using its patented technology Invisicare®. Skinvisible's primary objective is to license these prescription and over-the-counter products into the medical markets. Potential licensees include international and multi-national pharmaceutical, biotech and consumer goods companies seeking new products or life cycle management for their existing products. www.invisicare.com and www.skinvisible.com
- 网站
-
http://www.skinvisible.com
Skinvisible Pharmaceuticals, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Las Vegas，NV
- 类型
- 上市公司
- 创立
- 1999
- 领域
- patented polymer delivery systems for enhanced topical delivery、life cycle management for products coming off patent、ten international patents & numerous patents pending、pipeline of >30 products for licensing including Rx, OTC and cosmeceuticals、obesity和rare skin disease
地点
-
主要
获取路线
6320 S. Sandhill Rd
US，NV，Las Vegas，89120
Skinvisible Pharmaceuticals, Inc.员工
动态
-
Exciting news from Skinvisible's licensee of our Invisicare formulation for Netherton Syndrome ... https://lnkd.in/gXpdrMRR
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies | Quoin Pharmaceuticals, Inc.
investors.quoinpharma.com
-
Excited that Skinvisible's transdermal obesity development is featured in Drug Development & Delivery publication. https://lnkd.in/g4vQnpsq
-
-
Excited to share our transdermal obesity formulation data for GLP-1 antagonists and CB-1 agonists. This follows our recent announcements regarding our patent application for these innovative formulations. Read more https://lnkd.in/gvqRT34V
-
-
Skinvisible announces expansion of our Obesity Patent! This new application broadens the scope of our initial patent, with a wider range of active ingredients and additional conditions beyond obesity. Check out the details here: https://lnkd.in/gBQiHRT6
-
-
Skinvisible Pharmaceuticals, Inc.转发了
Skinvisible Submits Obesity Patent for Advanced Transdermal Treatment - Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Enhanced by Invisicare Topical / Transdermal Delivery System https://lnkd.in/ge5KRCG6
-
-
Skinvisible Submits Obesity Patent for Advanced Transdermal Treatment - Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Enhanced by Invisicare Topical / Transdermal Delivery System https://lnkd.in/ge5KRCG6
-
-
Skinvisible Submits Obesity Patent for Transdermal Treatment: Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Enhanced by Invisicare Topical / Transdermal Delivery System https://lnkd.in/ge5KRCG6
Skinvisible Inc. News and Press Releases
skinvisible.com